Home
HelpTest Code SHBG1 Sex Hormone-Binding Globulin, Serum
Specimen Required
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Useful For
Diagnosis and follow-up of women with signs or symptoms of androgen excess (eg, polycystic ovarian syndrome and idiopathic hirsutism)
An adjunct in monitoring sex-steroid and antiandrogen therapy
An adjunct in the diagnosis of disorders of puberty
An adjunct in the diagnosis and follow-up of anorexia nervosa
An adjunct in the diagnosis of thyrotoxicosis (tissue marker of thyroid hormone excess)
A possible adjunct in diagnosis and follow-up of insulin resistance and cardiovascular and type 2 diabetes risk assessment, particularly in women
Method Name
Immunoenzymatic Assay
Reporting Name
Sex Hormone-Binding Globulin, SSpecimen Type
SerumSpecimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 14 days | |
| Frozen | 90 days | ||
| Ambient | 7 days |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | OK |
| Gross icterus | OK |
Clinical Information
Sex hormone-binding globulin (SHBG), a 95 kDa homodimer, is the blood transport protein for testosterone and estradiol. SHBG is mainly produced in the liver and has a half-life of approximately seven days. SHBG binds reversibly to sex steroids. SHBG has a relatively high-binding affinity to dihydrotestosterone (DHT), medium affinity to testosterone and estradiol, and exhibits a low affinity to estrone, dehydroepiandrosterone, androstenedione, and estriol. Albumin, which exists at physiologically higher concentrations than SHBG, also binds to sex steroids, although with a much lower binding affinity (eg, about 100 times lower for testosterone).
Decreased SHBG serum concentrations are associated with conditions in which elevated androgen concentrations are present, or the effect of androgen on its target organs is excessive. Because of the high-binding affinity of SHBG to DHT, as compared to estradiol, SHBG has profound effects on the balance between bioavailable androgens and estrogens. Increased SHBG concentrations may be associated with signs and symptoms of hypogonadism in men, while decreased concentrations can result in androgenization in women. SHBG is regulated by insulin, and a low SHBG concentration often indicates insulin resistance and, consequently, may be a predictor of type 2 diabetes.
Endogenous or exogenous thyroid hormones or estrogens increase SHBG concentrations. In men, there is also an age-related gradual rise, possibly secondary to the mild age-related fall in testosterone production. This process can result in bioavailable testosterone concentrations that are much lower than would be expected based on total testosterone measurements alone.
Reference Values
CHILDREN:
Males
|
Tanner Stages |
Mean Age |
Reference Interval (nmol/L) |
|
Stage I |
10.4 |
17-135 |
|
Stage II |
11.1 |
21-114 |
|
Stage III |
12.7 |
12-138 |
|
Stage IV |
14.5 |
7.7-67 |
|
Stage V |
14.2 |
3.9-40 |
Females
|
Tanner Stages |
Mean Age |
Reference Interval (nmol/L) |
|
Stage I |
10.5 |
16-182 |
|
Stage II |
10.9 |
24-121 |
|
Stage III |
12.5 |
18-87 |
|
Stage IV |
14 |
7.7-108 |
|
Stage V |
14.9 |
10-79 |
ADULTS:
Males
≥18 years: 13.3-89.5 nmol/L
Females
18-46 years: 18.2-135.5 nmol/L
47-91 years: post-menopausal: 16.8-125.2 nmol/L
Interpretation
Many conditions of mild-to-moderate androgen excess in women, particularly polycystic ovarian syndrome, are associated with low sex hormone-binding globulin (SHBG) concentrations. A defect in SHBG production could lead to bioavailable androgen excess, in turn causing insulin resistance that depresses SHBG concentrations further. There are rare cases of SHBG variants that follow this pattern. SHBG concentrations are typically very low in these individuals. However, in most patients, SHBG concentrations are mildly depressed or possibly within the lower part of the reference interval. In these patients, the primary problem may be androgen overproduction, insulin resistance, or both.
Adult SHBG concentrations in adolescent boys with signs of precocious puberty support the condition is testosterone driven, rather than representing premature adrenarche.
Therapies/behavior alterations that may potentially increase SHBG concentrations include reducers of bioactivity of androgens (eg, androgen receptor antagonists, alpha-reductase inhibitors) or reduction of insulin resistance (eg, weight loss, metformin, peroxisome proliferator-activated receptor gamma agonists). Clinical assays may not be available for many therapeutic synthetic androgens and estrogens (eg, ethinyl-estradiol). In those instances, increasing SHBG concentrations may be associated with anti-androgen or estrogen therapy, while SHBG reduction can be associated with androgen treatment.
Patients with anorexia nervosa have high SHBG concentrations. With successful treatment, concentrations start to decline as nutritional status improves. Normalization of SHBG precedes, and may be predictive of, future normalization of reproductive function.
Thyrotoxicosis increases SHBG concentrations. In situations when assessment of true functional thyroid status may be difficult (eg, patients receiving amiodarone treatment, individuals with thyroid hormone transport-protein abnormalities, patients with suspected thyroid hormone resistance or suspected inappropriate thyrotropin [TSH] secretion, such as a TSH-secreting pituitary adenoma), elevated SHBG concentrations suggest tissue thyrotoxicosis, while normal levels indicate euthyroidism or near-euthyroidism.
SHBG is also produced by placental tissue and, therefore, values will be elevated during pregnancy. Reference ranges for pregnant women have not been established at our institution.
In patients with known insulin resistance, "metabolic syndrome," or high risk of type 2 diabetes (eg, women with a history of gestational diabetes), low SHBG concentrations may predict progressive insulin resistance, cardiovascular complications, and progression to type 2 diabetes. An increase in SHBG concentrations may indicate successful therapeutic intervention.
A genetic variant of SHBG (Asp327>Asn) introduces an additional glycosylation site in 10% to 20% of the population, resulting in significantly slower degradation. These individuals tend to have higher SHBG concentrations for any given level of other factors influencing SHBG.
In laboratories without access to bioavailable testosterone or equilibrium dialysis-based "true" free testosterone assays, sex hormone-binding globulin measurement is crucial in cases when assessment of the free testosterone fraction (free androgen index or calculated free testosterone) is required. At Mayo Clinic Laboratories, both bioavailable testosterone (TTBS / Testosterone, Total and Bioavailable, Serum) and free testosterone (TGRP / Testosterone, Total and Free, Serum) measurements are available. Free testosterone (TGRP) is measured by equilibrium dialysis, obviating the need for sex hormone-binding globulin measurements to calculate free androgen fractions.
Cautions
In rare cases, some individuals can develop antibodies to mouse or other animal antibodies (often referred to as human anti-mouse antibodies [HAMA] or heterophile antibodies), which may cause interference in some immunoassays. Caution should be used in interpretation of results, and the laboratory should be alerted if the result does not correlate with the clinical presentation.
For patients presenting with cirrhosis or subclinical thyroid conditions, carefully evaluate results as these conditions can potentially cause erroneous sex hormone-binding globulin (SHBG) results.
SHBG results should be interpreted in light of the total clinical presentation of the patient, including symptoms, clinical history, data from additional tests, and other appropriate information.
Method Description
The Access SHBG (sex hormone-binding globulinSHBG) assay is a sequential 2-step immunoenzymatic (sandwich) assay. Patient sample is added to a reaction vessel along with paramagnetic particles coated with monoclonal anti-SHBG antibody and saline buffer with proteins. After incubation in a reaction vessel, materials bound to the solid phase are held in a magnetic field, while unbound materials are washed away. A second monoclonal anti-SHBG antibody conjugated to alkaline phosphatase is added to the reaction vessel. After the second incubation in the reaction vessel, materials bound to the solid phase are held in a magnetic field, while unbound materials are washed away. Then, the chemiluminescent substrate is added to the vessel, and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of SHBG in the sample. The amount of analyte in the sample is determined from a stored, multi-point calibration curve.(Package insert: Access SHBG Sex Hormone-Binding Globulin, A48617. Beckman Coulter, Inc; 04/2020)
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
84270
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| SHBG1 | Sex Hormone-Binding Globulin, S | 13967-5 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| SHBG1 | Sex Hormone-Binding Globulin, S | 13967-5 |
Day(s) Performed
Monday through Saturday